Results 51 to 60 of about 8,545 (210)

Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial : A Randomized, Placebo-Controlled Trial [PDF]

, 2023
Molnupiravir is an orally administered antiviral authorized for COVID-19 treatment in adults at high risk of progression to severe disease. Here, we report secondary and post hoc analyses of participants' self-reported symptoms in the MOVe-OUT trial ...
Brotons, Carlos, Brown, Michelle, Coetzee, Kathleen, De Anda, Carisa, Du, Jiejun, Guan, Yanfen, Johnson, Matthew G., Kozlov, Roman, Lopez, Rudy, Norquist, Josephine M., Paschke, Amanda, Puenpatom, Amy, Santiaguel, Joel, Surber, Joseph, Universitat Autònoma de Barcelona, Weinberg, Aaron, Williams-Diaz, Angela, Zhang, Ying, Zhao, Yujie   +18 more
core   +1 more source

Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences

Bulletin of the National Research Centre, 2022
Background The study was aimed at encapsulating the evidence of in vitro and in vivo antiviral activities of molnupiravir and its active form against highly pathogenic SARS-CoV-2, the pathogen responsible for COVID-19, and finding out the efficacy and ...
Shivali Singla, Sachin Goyal
doaj   +1 more source

Comparison of the acceptability and safety of molnupiravir in COVID-19 patients aged over and under 80 years

Aging and Health Research, 2023
Background: Molnupiravir is being widely used as a treatment for coronavirus disease 2019 (COVID-19); however, its acceptability and safety in older patients aged ≥ 80 years in real-world clinical practice is not well understood.
Kohei Fujita, Osamu Kanai, Hiroaki Hata, Kenjiro Ishigami, Kazutaka Nanba, Naoki Esaka, Koichi Seta, Tadashi Mio, Takao Odagaki   +8 more
doaj   +1 more source

Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19

The Lancet Regional Health. Western Pacific, 2023
Summary: Background: Real-world data is currently limited on the association between oral antiviral therapy and healthcare system burden in patients with mild-to-moderate COVID-19.
Abraham Ka-Chung Wai, Crystal Ying Chan, Annie Wai-Ling Cheung, Kailu Wang, Sunny Ching-Long Chan, Teddy Tai-Loy Lee, Luke Yik-Fung Luk, Edmond Tsz-Fung Yip, Joshua Wing-Kei Ho, Omar Wai-Kiu Tsui, Kelly Wing-Yin Cheung, Shiyeow Lee, Chak-kwan Tong, Tafu Yamamoto, Timothy Hudson Rainer, Eliza Lai-Yi Wong   +15 more
doaj   +1 more source

Molnupiravir: A new candidate for COVID‐19 treatment [PDF]

Pharmacology Research & Perspectives, 2021
AbstractThe novel coronavirus disease 2019 (COVID‐19) emerged in late December 2019 in china and has rapidly spread to many countries around the world. The effective pharmacotherapy can reduce the mortality of COVID‐19. Antiviral medications are the candidate therapies for the management of COVID‐19.
Fariba Pourkarim, Samira Pourtaghi-Anvarian, Haleh Rezaee   +2 more
openaire   +3 more sources

Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent

Antibiotics, 2021
Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly resulted in a global pandemic with approximately 4 million deaths.
Ching-Chi Lee, Chih-Chia Hsieh, Wen-Chien Ko   +2 more
doaj   +1 more source

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial [PDF]

, 2022
BackgroundThe safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19.
Butler, Christopher, IRVING, GREG, PANORAMIC Trial Collaborative Group‡   +2 more
core   +2 more sources

Effectiveness of Antiviral Therapy in Highly-Transmissible Variants of SARS-CoV-2: A Modeling and Simulation Study. [PDF]

, 2022
As of October 2021, neither established agents (e.g., hydroxychloroquine) nor experimental drugs have lived up to their initial promise as antiviral treatment against SARS-CoV-2 infection.
Chaccour, Carlos, Hammann, Felix, Kern, Charlotte, Schöning, Verena   +3 more
core   +1 more source

Molnupiravir When Used Alone Seems to Be Safe and Effective as Outpatient COVID-19 Therapy for Hemodialyzed Patients and Kidney Transplant Recipients

Viruses, 2022
Background: Molnupiravir demonstrated an in vitro antiviral activity against positive-sense RNA viruses, including SARS-CoV-2. The study aimed to present the results of outpatient molnupiravir use in kidney transplant recipients and hemodialysis patients
Paweł Poznański, Hanna Augustyniak-Bartosik, Anna Magiera-Żak, Karolina Skalec, Katarzyna Jakuszko, Oktawia Mazanowska, Dariusz Janczak, Magdalena Krajewska, Dorota Kamińska   +8 more
doaj   +1 more source

Molnupiravir in unvaccinated patients with COVID-19 [PDF]

Drug and Therapeutics Bulletin, 2022
Abstract Overview of: Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. NEJM. 2021;doi:10.1056/NEJMoa2116044 [Epub ahead of print 16 Dec 2021].
openaire   +2 more sources